

Dear Alzheimer's Patient and Caregiver:

I'm writing to inform you about the Gammaglobulin Alzheimer's Partnership (GAP) Study: a clinical research study that's bringing people with Alzheimer's disease, their caregivers, doctors, and medical researchers together to evaluate an investigational drug for people with mild-to-moderate Alzheimer's disease.

About the GAP Study

The Gammaglobulin Alzheimer's Partnership (GAP) Study is designed to evaluate the effectiveness, safety, and tolerability of an investigational drug called Gammaglobulin – and to see if this investigational drug may slow the progression of Alzheimer's and its symptoms.

Gammaglobulin is a form of Immune Globulin Intravenous, or IGIV. IGIV has been approved by the FDA for use with other conditions, and doctors and medical researchers are now evaluating its effectiveness, safety, and tolerability when it is used for Alzheimer's disease. Researchers believe that IGIV may act on some of the underlying causes of Alzheimer's, instead of just on Alzheimer's symptoms.

In this study, IGIV will be evaluated alongside standard-of-care medications for Alzheimer's. Patients who participate in the study will continue taking their current Alzheimer's medications.

What does study participation include?

Participation in this study will last approximately 20 months (one year and 8 months). All participants receive the following, at no cost:

- **Study drugs** – either IGIV or placebo (an inactive substance designed to have no effect on health). Every participant will have a random, 2-in-3 chance of receiving IGIV.
- **Study-related care and close monitoring**, both at the study clinic and potentially at the participant's home.
- **Study clinic visits**, at which the participant's physical and psychological health will be evaluated.

Who is eligible to participate?

Patients may be eligible to participate in the GAP Study if they:

- Are 50 to 89 years old.
- Have been diagnosed with probable mild-to-moderate Alzheimer's disease.
- Have a study partner (a spouse, child, sibling, or other caregiver) who can be present at every study visit to monitor the participant, and to help him or her complete key study procedures.

Find out if participation may be right for you.

Please respond for more information, or to see if you or someone you know may be eligible to participate.

University of Iowa

**Attn: Karen Ekstam-Smith, RN
(319) 353-5158**

Whether or not you are interested in this study, I also encourage you to speak with your doctor about all the treatment options that may be available to you, or to anyone in your care.

Thank you very much for this moment of your time.

Sincerely,

Susan K. Schultz, M.D.

University of Iowa

Attn: Karen Ekstam-Smith, RN